The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

Introduction: Mineralocorticoid receptor antagonists (MRAs) and sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce the risk of kidney failure in chronic kidney disease (CKD). We performed an analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) t...

全面介紹

書目詳細資料

發表在:	Kidney International Reports
Main Authors:	Michele Provenzano, Niels Jongs, Priya Vart, Bergur V. Stefánsson, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
格式:	Article
語言:	英语
出版:	Elsevier 2022-03-01
主題:	chronic kidney disease DAPA-CKD dapagliflozin hyperkalemia mineralocorticoid receptor antagonists sodium–glucose cotransporter-2 inhibitor
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S246802492101603X